Free Trial

HEALTHCARE: Bureau Veritas (BVIFP: A3): FY24

HEALTHCARE

Good numbers in line with estimates

  • Revenue €6.24bn matched estimates +6.4% yoy, +10.2% organically
  • Adj Op Profit €996m +7.1% yoy; Adj Op Margin of 16% a slight uptick of 38bps CER
  • FCF €843m +27.9% yoy a new record
  • ND/EBITDA 1.06x slightly up from 0.92x but still low
  • Guidance mid-high single-digit organic revenue growth
  • Issued twice in 2024 (2031 & 2036), now has A3 rating from Moody's. Next maturity Sep 26
  • The key question for BVI is M&A strategy following the termination of SGS merger talks. BVI said that they still believe in consolidation.
86 words

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.

Good numbers in line with estimates

  • Revenue €6.24bn matched estimates +6.4% yoy, +10.2% organically
  • Adj Op Profit €996m +7.1% yoy; Adj Op Margin of 16% a slight uptick of 38bps CER
  • FCF €843m +27.9% yoy a new record
  • ND/EBITDA 1.06x slightly up from 0.92x but still low
  • Guidance mid-high single-digit organic revenue growth
  • Issued twice in 2024 (2031 & 2036), now has A3 rating from Moody's. Next maturity Sep 26
  • The key question for BVI is M&A strategy following the termination of SGS merger talks. BVI said that they still believe in consolidation.